Hormesis and its place in nonmonotonic dose-response relationships: Some scientific reality checks

Environmental Health Perspectives

Volumn 115, Issue 4, 2007, Pages 500-506

  Mushak, Paul ^a  

^a PB Associates   (United States)

Author keywords

Bidirectional dose response; Biphasic dose response; Hormesis; Nonmonotonic dose response

Indexed keywords

ARSENIC; CHEMICAL COMPOUND; ENDOCRINE DISRUPTOR; POLYCYCLIC AROMATIC HYDROCARBON; XENOBIOTIC AGENT;

BIOTRANSFORMATION; BRONCHIECTASIS; CHEMICAL CARCINOGENESIS; CONSENSUS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL PROTECTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH CARE POLICY; HORMESIS; HUMAN; IONIZING RADIATION; LUNG CANCER; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICITY TESTING;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; HEALTH POLICY; RISK ASSESSMENT; TERMINOLOGY;

EID: 34247136838     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.9619     Document Type: Review

References (91)

1. Abel EL, Jacobsen S, Sherwin BJ. 1983. In utero ethanol exposure: functional and structural brain damage. Neurobehav Toxicol Teratol 5:39-146.
2. Académie Nationale de Médecine. 2005. Joint Report with Académie des Sciences, Institut de France. Dose-Effect Relationships and the Estimation of Carcinogenic Effects of Low doses of Ionizing Radiation. Available: http://www.academie-sciences.fr/ publications/rapports/pdf/dose_effet_07_04_05.pdf [accessed 4 December 2006].
3. American Chemical Society. 1991. Chemical Abstracts. Vols 114, 115. Columbus, OH:American Chemical Society.
4. Buchet JP, Lauwerys R.1994. Inorganic arsenic metabolism in humans. In: Arsenic Exposure and Health (Chappell WR, Abernathy CO, Cothern CR, eds). Northwood, Middlesex, UK:Science and Technolgy Letters, 181-189.
5. Calabrese EJ. 2001a. Adenosine: biphasic dose responses. Crit Rev Toxicol 31:539-551.
6. Calabrese EJ. 2001b. Androgens: biphasic dose responses. Crit Rev Toxicol 31:517-522.
7. Calabrese EJ. 2001c. Apoptosis: biphasic dose responses. Crit Rev Toxicol 31:607-613.
8. Calabrese EJ. 2001d. Cell migration/chemotaxis: biphasic dose responses. Crit Rev Toxicol 31:615-624.
9. Calabrese EJ. 2001e. Dopamine: biphasic dose responses. Crit Rev Toxicol 31:563-583.
10. Calabrese EJ. 2001f. Estrogen and related compounds: biphasic dose responses. Crit Rev Toxicol 31:503-515.
11. Calabrese EJ. 2001g. 5-Hydroxytryptamine (serotonin): biphasic dose responses. Crit Rev Toxicol 31:553-561.
12. Calabrese EJ. 2001h. Nitric oxide: biphasic dose responses. Crit Rev Toxicol 31:489-501.
13. Calabrese EJ. 2001i. Opiates: biphasic dose responses. Crit Rev Toxicol 31:585-604.
14. Calabrese EJ. 2001j. Prostaglandins: biphasic dose responses. Crit Rev Toxicol 31:475-487.
15. Calabrese EJ. 2002. Hormesis: changing view of the dose-response, a personal account of the history and current status. Mutat Res 511:181-189.
16. Calabrese EJ. 2005a. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) responses. Crit Rev Toxicol 35:462-582.
17. Calabrese EJ. 2005b. Toxicological awakenings: the rebirth of hormesis as a central pillar of toxicology. Toxicol Appl Pharmacol 204:1-8.
18. Calabrese EJ, Baldwin LA. 1997. A quantitatively based methodology for the evaluation of chemical hormesis. Hum Ecol Risk Assess 3:545-554.
19. Calabrese EJ, Baldwin LA. 2001a. Hormesis: a generalizable and unifying hypothesis. Crit Rev Toxicol 31: 353-424.
20. Calabrese EJ, Baldwin LA. 2001b. The frequency of U-shaped dose-responses in the toxicological literature. Toxicol Sci 62:330-338.
21. Calabrese EJ, Baldwin LA. 2001c. U-shaped dose-responses in biology, toxicology, and public health. Ann Rev Publ Health 22:15-33.
22. Calabrese EJ, Baldwin LA. 2002a. Defining hormesis. Hum Exp Toxicol 21:91-97.
23. Calabrese EJ, Baldwin LA. 2002b. Hormesis and high-risk groups. Reg Toxicol Pharmacol 35:414-428.
24. Calabrese EJ, Baldwin LA. 2003a. Chemotherapeutics and hormesis. Crit Rev Toxicol 33:305-353.
25. Calabrese EJ, Baldwin LA. 2003b. Ethanol and hormesis. Crit Rev Toxicol 33:407-424.
26. Calabrese EJ, Baldwin LA. 2003c. Hormesis at the National Toxicology Program (NTP): evidence of hormetic dose responses in NTP dose-range studies. Nonlinear Biol Toxicol Med 1:455-467.
27. Calabrese EJ, Baldwin LA. 2003d. Inorganics and hormesis. Crit Rev Toxicol 33:215-304.
28. Calabrese EJ, Baldwin LA. 2003e. Peptides and hormesis. Crit Rev Toxicol 33:355-405.
29. Calabrese EJ, Baldwin LA. 2003f. The hormetic dose-response model is more common than the threshold model in toxicology. Toxicol Sci 71:246-250.
30. Calabrese EJ, Baldwin LA, Holland CD. 1999. Hormesis: a highly generalizable and reproducible phenomenon with important implications for risk assessment. Risk Anal 19:261-281.
31. Calabrese EJ, Blain R. 2005. Occurrence of hormetic dose responses in the toxicological literature, the hormetic data base: an overview. Toxicol Appl Pharmacol 202:289-301.
32. Calabrese EJ, Cook R. 2005. Hormesis: how it could affect the risk assessment process. Hum Exp Toxicol 24: 265-270.
33. Cardis E, Vrijheld M, Blettner M, Gilbert E, Hakama M, Hill C et al. 2005. Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ doi:10.1136/bmj. 38499.599861.EO [Online 29 June 2005].
34. CDC. 2005. Lead Poisoning in Young Children. A statement by the Centers for Disease Control and Prevention. Atlanta: Centers for Disease Control and Prevention.
35. Chapman PM. 2002. Defining hormesis: comments on Calabrese and Baldwin (2002). Hum Exp Toxicol 21:99-101.
36. Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder, and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888-892.
37. Chiou HY, Chiou ST, Hsu YH, Chou YL, Tseng CH, Wei ML, et al. 2001. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 153:411-418.
38. Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, et al. 2002. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 110:729-733.
39. Concha G, Vogler G, Lescano D, Nermell B, Vahter M. 1998. Exposure to inorganic arsenic metabolites during early human development. Toxicol Sci 44:185-190.
40. Conolly RB, Lutz WK. 2004. Nonmonotonic dose-response relationships: Mechanistic basis, kinetic modeling, and implications for risk assessment. Toxicol Sci 77:151-157.
41. Cook R, Calabrese EJ. 2006. The importance of hormesis to public health. Environ Health Perspect 114:1631-1635; doi:10.1289/EHP.8606 [Online 10 July 2006].
42. Crump K. 2001. Evaluating the evidence for hormesis: a statistical perspective. Crit Rev Toxicol 31:669-679.
43. Davis JM, Svendsgaard DJ. 1994. Nonmonotonic dose-response relationships in toxicological studies. In: Biological Effects of Low Level Exposures: Dose-Response Relationships (Calabrese EJ, ed). Boca Raton, FL:Lewis Publishers, 67-85.
44. Eaton Dl, Klaassen CD. 2003. Principles of toxicology. In: Casarett and Doull's Essentials of Toxicology (Klaassen CD, Watkins JB, eds). New York:McGraw-Hill, 6-20.
45. Ferreccio C, Gonzalez C, Milosavljevic V, Marshall G, Sancha AM, Smith AH. 2000. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 11:673-679.
46. Goyer RA, Liu J, Waalkes P. 2004. Cadmium and cancer of prostate and testis. Biometals 17:555-558.
47. ICRP. 2004. Low Dose Extrapolation of Radiation-Related Cancer Risk. Committee I Task Group Report. Stockholm: International Commission on Radiation Protection.
48. International Programme on Chemical Safety. 1992. Environmental Health Criteria 134. Cadmium. Geneva:International Programme on Chemical Safety.
49. Johansson L. 2003. Hormesis, an update of the present position. J Nucl Med Mol Imaging 30:921-933.
50. Kitchin KT. 2002. Defining, explaining and understanding hormesis. Hum Exp Toxicol 21:105-106.
51. Kitchin KT, Drane JW. 2005. A critique of the use of hormesis in risk assessment. Hum Exp Toxicol 24(5):249-253.
52. Kociba RJ, Keyes DG, Beyer JE, Carreon RM, Wade CE et al. 1978. Results of a 2-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 49:279-303.
53. Krestinina LY, Preston DL, Ostroumova EV, Degteva MO, Ron E, Vyushkova OV, et al. 2005. Protracted radiation exposure and cancer mortality in the Techa River cohort. Radiat Res 164:602-611.
54. Kurttio P, Pukkala E, Kahelin H, Auvinen A, Pekkanen J. 1999. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect 107:705-710.
55. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, et al. 2005. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 113:894-899.
56. Liu J, Xie Y, Duscharme DMK, Shen J, Diwan BA, Merrick BA et al. 2006. Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. Environ Health Perspect 114:404-411.
57. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, et al. 2001. Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 14:355-361.
58. Melnick R, Lucier G, Wolfe M, Hall M, Stancel G, Prins G, et al. 2002. Summary of the National Toxicology Program's report of the endocrine disruptors low-dose peer review. Environ Health Perspect 110:427-431.
59. Merriam Webster Inc. 2002 Webster's Third New International Dictionary. Unabridged. Springfield, MA:Merriam-Webster Inc.
60. Mushak P. 1992. Commentary. The landmark Needleman study of childhood lead poisoning: scientific and social aftermath. PSR Q 2:165-170.
61. NAS/NRC (National Academy of Sciences/National Research Council). 1983. Risk Assessment in the Federal Government: Managing the Process. Washington, DC:National Academy Press.
62. NAS/NRC (National Academy of Sciences/National Research Council). 1993. Measuring Lead Exposure in Infants, Children, and Other Sensitive Populations. Washington, DC:National Academy Press.
63. NAS/NRC (National Academy of Sciences/National Research Council). 1999. Arsenic in Drinking Water. Washington, DC:National Academy Press.
64. NAS/NRC (National Academy of Sciences/National Research Council). 2001. Arsenic in Drinking Water: 2001 Update. Washington, DC:National Academy Press.
65. NAS/NRC (National Academy of Sciences/National Research Council). 2006. Health Risks from Exposure to Low Levels of Ionizing Radiation. BEIR VII-Phase 2. Washington, DC:National Academy Press.
66. National Library of Medicine. Index Medicus. 1991. Vol 32. Bethesda, MD:National Library of Medicine.
67. NCRP. 2001. Evaluation of the Linear-Nonthreshold Dose-Response Model for Ionizing Radiation. NCRP Report No. 136. Bethesda, MD:National Council on Radiation Protection and Measurements.
68. Parkinson A. 2001. Biotransformation of xenobiotics. In: Casarett and Doull's Toxicology. The Basic Science of Poisons, 6th ed (Klaassen CD, ed). New York:McGraw-Hill, 141-143.
69. Perera FP, Rauh V, Whyatt RN, Tsai W-Y, Tang D, Diaz D et al. 2006. Effect of exposure to aromatic hydrocarbons on neurodevelopment in the first three years of life among inner city children. Environ Health Perspect doi: 10:1289/EHP.9084 [Online 24 April 2006].
70. Pickrell JA, Oehme FW. 2002. Invited response to definition of hormesis (EJ Calabrese and LA Baldwin). Hum Exp Toxicol 21:107-109.
71. Pollycove M, Feinendegen LE. 2001. Biological responses to low doses of ionizing radiation: detriment versus hormesis. Part 2. Dose responses of organisms. J Nucl Med 42:26N-32N, 37N.
72. Roberts SM. 2001. Another view of the scientific foundations of hormesis. Crit Rev Toxicol 31:631-635.
73. Rozman KK, Doull J. 2000. Dose and time as variables of toxicology. Toxicology 144:169-178.
74. Sheehan DM. 2006. No-threshold dose-response curves for nongenotoxic chemicals: findings and applications for risk assessment. Environ Res 100:93-99.
75. Sheehan DM, Willingham E, Gaylor D, Bergeron JM, Crews D. 1999. No threshold dose for estradiol-induced sex reversal of turtle embryos: how little is too much? Environ Health Perspect 107:155-159.
76. Smith AH, Goycolea M, Hague R, Biggs ML. 1998. Marked increase in bladder and lung cancer mortality in a region of northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660-669.
77. Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, et al. 2006. Increased mortality from lung cancer and bronchiectasis in young adults following exposure to arsenic in utero and early childhood. Environ Health Perspect doi: 10.1289/EHP.8832 [Online 27 March 2006].
78. Thayer KA, Melnick R, Burns K, Davis D, Huff J. 2005. Fundamental flaws of hormesis for public health decisions. Environ Health Perspect 113:1271-1276.
79. United Nations Scientific Committee on the Effects of Atomic Radiation. 2000. Biological Effects at Low Radiation Doses. Report to the General Assembly, with Scientific Annexes. Annex G: Vol II. Report no E.94.IX.2. New York:UNSCEAR.
80. Union of American Biological Societies. 1991. Biological Abstracts. Vols 91, 92. Philadelphia:Union of American Biological Societies.
81. Upton AC. 2001. Radiation hormesis: data and interpretations. Crit Rev Toxicol 31:681-695.
82. U.S. EPA. 2007. Integrated Risk Information System. Cincinnati, OH:U.S. Environmental Protection Agency, National Center for Environmental Assessment. Available: http://www.epa.gov/iris/index.html [accessed 21 February 2007].
83. Vahter M. 2000. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 112-113:209-217.
84. Waalkes MP, Rehm S, Devor DE. 1997. The effects of continuous testosterone exposure on spontaneous and cadmium-induced tumors in the male Fischer (F344/NCr) rat: loss of testicular response. Toxicol Appl Pharmacol 142:40-46.
85. Waalkes MP, Rehm S, Riggs CW, Bare RM, Devor DE, Poirier LA, et al. 1988. Cadmium carcinogenesis in male Wistar [Crl: (WI)BR] rats: dose-response analysis of tumor induction in the prostate and testes and in the injection site. Cancer Res 48:4656-4663.
86. Waalkes MP, Liu, Chen H, Yaxiong X, Achanzar WE, Zhou Y-S, et al. 2004. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J Natl Cancer Inst 96:466-474.
87. Waalkes MP, Ward JM, Liu J, Diwan B. 2003. Transplacental carcinogenicity of inorganic arsenic in the drinking water: Induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol 186:1387-1397.
88. Welshons WW, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. 2003. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ Health Perspect 111:994-1006.
89. WHO. 1996. Trace Elements in Human Nutrition and Health. Geneva:World Health Organization.
90. Yu L, Kalla K, Guthrie E, Vidrine A, Kimeski WT. 2003. Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase omega 1-1 and purine nucleoside phosphorylase polymorphisms in Europeans and indigenous Americans. Environ Health Perspect 111:1421-1427.
91. Yu Z, Loehr CV, Fisher KA, Louderback MA, Krueger SK, Dashwood RA, et al. 2006. In utero exposure of mice to dibenzo a,l pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. Cancer Res 66: 755-762.